WASHINGTON (Reuters) -Robert F. Kennedy Jr., President Donald Trump's pick to lead the top U.S. health agency, came under ...

Novavax Inc. closed 63.58% short of its 52-week high of $23.86, which the company reached on June 6th.

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Novavax Inc. closed 62.24% below its 52-week high of $23.86, which the company reached on June 6th.

The most recent trading session ended with Novavax (NVAX) standing at $9.34, reflecting a +1.3% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily loss of 1.46%.

Bullish option flow detected in Novavax (NVAX) with 5,702 calls trading, 1.1x expected, and implied vol increasing almost 10 points to 99.21%.

Idaho Sen. Brandon Shippy proposes bill to ban mRNA vaccines until 2035 by incorrectly categorizing them as gene therapy, ...

Check the time stamp on this data. Updated AI-Generated Signals for Novavax Inc. (NVAX) available here: NVAX. Type a few ...

The average of price targets set by Wall Street analysts indicates a potential upside of 81.6% in Novavax (NVAX). While the effectiveness of this highly sought-after metric is questionable, the ...

Robert F. Kennedy Jr., President Donald Trumps nominee to lead the U.S. Department of Health and Human Services (HHS), faced ...

Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees ...